Cassava Sciences: Unconvincing Open Label Studies, Upcoming Phase 3, Risky AD Bet (SAVA)

Memory lapses, forgetting things, degenerative disease. Brain problems. Parkinson and alzheimer desease. Mental health. Face side view


The Alzheimer’s Disease (“AD”) space is a very difficult and volatile space right now. Here, you will see a large number of sympathetic volatility in stock prices. So, if one company comes out with positive data, other AD companies go up along with it. If another company

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *